羟苯磺酸钙联合阿卡波糖治疗糖尿病视网膜病变伴白内障的临床有效性和安全性研究

Calcium dobesilate combined with acarbose in treatment of diabetic retinopathy with cataract

目的 探讨和分析羟苯磺酸钙与阿卡波糖在糖尿病视网膜病变伴白内障患者中的联合应用价值。方法 选择2017年1月至2018年12月期间本院所收治的86例(111眼)糖尿病视网膜病变伴白内障患者作为临床研究对象,采用随机数字表法随机分为观察组44例(57眼)和对照组42例(54眼),对照组患者采用阿卡波糖治疗,观察组患者则在对照组的基础上加用羟苯磺酸钙治疗,并分别对两组患者的临床治疗情况、炎症因子变化情况及不良反应发生情况进行比较和分析。结果 与对照组患者相比,观察组患者临床治疗的总有效率[91.23%(52/57)]明显提高,而无效率[8.77%(5/57)]则明显降低,差异均有统计学意义(均P<0.05);观察组患者治疗后炎症因子TNF-α为(0.89±0.19)ng/mL,IL-6为(92.30±10.34)ng/L,Hs-CRP为(7.35±0.84)mg/L,明显低于治疗后的对照组,差异均有统计学意义(均P<0.05)。观察组患者恶心呕吐、腹泻腹痛、胃部不适、皮肤过敏等不良反应总发生率为13.64%(6/44),对照组为14.28%(6/42),但差异无统计学意义(P>0.05)。结论 羟苯磺酸钙联合阿卡波糖能够通过对糖尿病视网膜病变伴白内障患者细胞炎症因子水平的调节而改善其临床治疗的有效性和安全性。

Objective To explore the value of calcium dobesilate and acarbose in the treatment of diabetic retinopathy with cataract. Methods From January, 2017 to December, 2018, 86 patients (111 eyes) with diabetic retinopathy and cataract treated in our hospital were selected as clinical research subjects. By randomized digital table method, the patients were divided into an observation group with 44 cases (57 eyes) and a control group with 42 cases (54 eyes). The control group were treated with acarbose, and the observation group with calcium dobesilate and acarbose. The clinical treatment, the changes of inflammatory factors, and the occurrence of adverse reactions ofthe two groups were compared and analyzed. Results The total effective rate was 91.23%(52/57) and the ineffective rate was 8.77%(5/57) in the observation group, which were better than those in the control group (P < 0.05). After the treatment, the levels of TNF-α, IL-6, and Hs-CRP were (0.89±0.19) ng/ml,(92.30±10.34) ng/L, and (7.35±0.84) mg/L in the observation group, which were significantly lower than those in the control group (all P < 0.05). The total incidence of adverse reactions, including nausea and vomiting, diarrhea, abdominal pain, stomach discomfort and skin allergies, was 13.64%(6/44) in the observation group, with no statistical difference from that of the control group (P > 0.05). Conclusions Calcium dobesilate combined with acarbose could improve the efficacy and safety of clinical treatment by regulating the levels of cellular inflammatory factors.